1868-1050.jpg

ANTIGENS Seasonal flu is a common infectious disease of the respiratory tract caused by influenza virus. There are four types of influenza virus, influenza type A, B, C, and D. The A and B types are of most interest to the medical community because they are the culprits for seasonal epidemics. Occasionally, influenza A, like the A/California/04/09 (H1N1) and A/Hong Kong/1/1968 (H3N2), can even cause global pandemics.

© Premier Research

Cancer immunotherapy exploits the body’s own immune system to fight against cancer. CAR-T cell therapy is one of the breakthrough approaches that involves re-engineering a patient’s own
T cells to recognize and eradicate cancer.

Picture: Pistoia Alliance

The pharmaceutical industry has made significant advances in collaboration over the past two years, and I have seen many examples amongst Pistoia Alliance members of the power of cooperative working. It is imperative that the industry continues to build on these successes.

Kjerstin_Michaela/Pixabay

Sanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology.

Source: BIOCOM/Deutsche Börse

Early December, Deutsche Börse has started BIOTECH Insight, a new information service on the German biotech industry.

© Theracell

US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece.

Picture: Neyroo

Building on a relentless commitment to customer service and innovation, Beckman Coulter Life Sciences debuts a powerful new interactive customer resource with the launch of its Digital Campus. The 3D platform provides greater access to the company’s resources regardless of physical location and allows users to control their experience including the chance to get up close and personal with products and experts.

John_Hodgson.jpg

Despite a couple of notable ‘firsts’ for European public biotech financing, biotech’s COVID-19 bubble may be about to burst. Virus fears pushed both private and public investors toward biotech, but vaccination successes have changed the sentiment. Now, it seems there are simply too many biotech companies, especially in Europe.

Lund-based Immunovia will need a new CEO, because Patrik Dahlen wants to leave the diagnostics company for personal reasons.

Source: BIOCOM AG

The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!